SAN CARLOS, Calif., Aug. 29 /PRNewswire/ -- Nuvelo, Inc. today announced that new data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 trial evaluating recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with acute coronary syndromes (ACS) will be presented at the World Congress of Cardiology 2006 taking place from September 2nd through the 5th in Barcelona, Spain. Nuvelo management will host a conference call to present and discuss the data on Tuesday, September 5th at 4:30 p.m. EDT.
The presentation details are as follows:
Poster Session (Program #3897): “Tissue-factor/factor VIIa inhibition with higher-dose rNAPc2 reduces ischemia in patients with NSTE-ACS managed with an early invasive strategy in ANTHEM-TIMI 32"
Date/Time: Tuesday, September 5, 2006, 8:30 - 12:30 a.m. CEST
Presenter: Robert P. Giugliano, M.D., S.M., investigator, TIMI Study Group, associate physician, Brigham and Women’s Hospital and assistant professor of medicine, Harvard Medical School
Conference Call Information
Nuvelo will hold a conference call on September 5, 2006 at 4:30 p.m. Eastern Time to discuss the data presentation. Speakers will include Steven Deitcher, M.D., vice president and chief medical scientist and Ted W. Love, M.D., chairman and chief executive officer. To participate in the conference call, please dial 866-713-8567 for domestic callers and 617-597-5326 for international callers and reference conference passcode, 21826949. A telephone replay of the conference call will be available through Tuesday, September 12, 2006. To access the replay, please dial 888-286-8010 for domestic callers and 617-801-6888 for international callers and reference conference passcode, 96057794.
This call is also being webcast by Thomson/CCBN and can be accessed at Nuvelo’s website at www.nuvelo.com or by visiting Thomson/CCBN’s StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic in four Phase 3 clinical trials for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex which recently completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, which includes NU206 for the potential treatment of chemotherapy/radiation therapy- induced mucositis, as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Contact: Nicole Estrin Foderaro Associate Director of Corporate Communications & IR 650-517-8472 nfoderaro@nuvelo.com Carolyn Bumgardner Wang WeissComm Partners, Inc. 415-946-1065 carolyn@weisscommpartners.com
Nuvelo, Inc.
CONTACT: Nicole Estrin Foderaro, Associate Director of CorporateCommunications & IR of Nuvelo, Inc., +1-650-517-8472 ornfoderaro@nuvelo.com; or Carolyn Bumgardner Wang of WeissComm Partners,Inc. for Nuvelo, Inc., +1-415-946-1065 or carolyn@weisscommpartners.com
Web site: http://www.nuvelo.com/
